Search

Levodopa

The first developed drug product that was approved by the FDA was a levodopa and carbidopa combined product called Sinemet that was approved on May 2, 1975[A177781,L6133]. … Levodopa can be metabolised to dopamine on either side of the blood-brain barrier and so it is generally administered with a dopa decarboxylase inhibitor like carbidopa to prevent metabolism until after

Almitrine

It is used in the treatment of chronic obstructive pulmonary disease. … It is also reported to have a potentially beneficial effect in treating the noctural oxygen desaturation without impairing the quality of sleep.

Ioversol

[L41780] Ioversol was approved by the FDA in 1989 and is currently indicated for computed tomographic (CT) imaging and contrast enhancement in peripheral arteriography, coronary arteriography, and left … Ioversol is a non-ionic compound with a tri-iodinated benzene ring used as a contrast dye in diagnostic procedures to visualize different types of organs and tissues.

Huperzine A

The botanical has been used in China for centuries for the treatment of swelling, fever and blood disorders. Recently in clinical trials in China, it has demonstrated neuroprotective effects. … Huperzine A, is a naturally occurring sesquiterpene alkaloid found in the extracts of the firmoss _Huperzia serrata_.

Poliovirus type 2 antigen (formaldehyde inactivated)

Poliovirus type 2 antigen is a suspension of poliovirus Type 2 (MEF-1) used in the active immunization of infants (as young as 6 weeks of age), children, and adults for the prevention of poliomyelitis

DL-dimyristoylphosphatidylcholine

A synthetic phospholipid used in liposomes and lipid bilayers for the study of biological membranes. It is used in commercial drug preparations to solubilize drugs for injection [A32711]

DL-alpha tocopheryl acetate

Semaglutide

Semaglutide was developed by Novo Nordisk and approved by the FDA for subcutaneous injection in December 2017.[L8681] The tablet formulation was approved for oral administration in September 2019. … [A186053] In June 2021, semaglutide was approved by the FDA for chronic weight management in adults with general obesity or overweight who have at least one weight-related condition, marking semaglutide

Dulaglutide

[A236070] Dulaglutide was initially approved by the FDA in 2014, and in February 2020 was approved for use in patients with T2DM and multiple cardiovascular risk factors for the prevention of cardiovascular … therapy to diet and exercise in the management of 2 diabetes (T2DM).

Amrinone

It is used in the treatment of congestive heart failure.